Leading biotechnology company MiRXES launched the first edition of the MiRXES Translator Program at the Singapore Week of Innovation and Technology (SWITCH).
MiRXES Translator Program is Southeast Asia’s first business and clinical advisory programme backed by science that bridges post-incubation ideation and post-accelerator growth. The program is a collaboration with global innovation platform Plug and Play.
The first of its kind, MiREXS Translator Program will support select high-growth potential companies to fast-track the commercialisation and adoption of preventive healthcare solutions, and translate that to revenue growth. The aim of doing so is to improve population health outcomes collectively.
Also read: How can startups automate processes to save time and money
“With our rich startup experience and extensive networks, MiRXES is excited to expand our role in the biotechnology and preventive healthcare sector by enabling multi-stakeholder partnerships and connecting companies with resources to increase the adoption of preventive healthcare solutions globally,” said Dr Lihan Zhou, Co-Founder and CEO of MiRXES.
MiRXES is a Singapore-headquartered biotech company that discovers and develops accurate and affordable preventive healthcare solutions and makes them accessible to all. They are focused on saving lives and improving health economics and outcomes through RNA-powered disease early detection and precision genomic tests.
MiRXES also launched and operates the Early Medical Centre, the region’s first healthcare innovation centre. The facility takes a unique, individualised approach to health, and is equipped with world-class facilities that serves as an aggregation hub for diagnostic solutions.
Co-generating business milestones
Through MiRXES Translator Program investor-partner partnership, MiRXES will actively co-generate measurable business milestones and results while sharing risks and rewards with companies enrolled in the programme, assisting them in growing and scaling their business efficiently and effectively.
MiRXES will enable the acceleration of their growth by contributing its research, manufacturing, and clinical diagnostic capabilities to validate products and provide cost advantage through economies of scale. Companies taking part in the program will also have access to the Early Medical Centre, where they will be able to validate their pricing and business viability.
“Besides investing capital through the MiRXES Translator Program, MiRXES is delighted to share our knowledge from operating some of the world’s most sophisticated laboratories where we pioneered clinical applications of cutting-edge research in RNA biomarkers and help these startups gain a footing in the industry,” said Zhou.
Also read: Bridging the gap between digital literacy and the financial services industry
Companies in the program will also receive support from MiRXES in regionalising their businesses through MiRXES’s infrastructures in Southeast Asia. Through their network, MiRXES will also facilitate partnerships between venture funds, medical partners, government, hospitals, and adopters,
MiRXES will be working with the shortlisted startups to run an extensive programme to develop and enhance their reach within the preventive healthcare sector. Depending on the startup’s maturity, the collaboration could span solution optimisation, pilot production, clinical advisory, and market validation.
Plug and Play, a highly successful investor and preferred innovation partner for major corporations, will assess applicants and curate suitable emerging preventive health-focused technology startups for the MiRXES Translator Program.
“Our goal is to provide a line-of-sight into the most innovative startups shaping the healthcare and biotechnology industry globally,” said Jupe Tan, Managing Partner of Plug and Play APAC.
“We are delighted to be working with MiRXES for their Translator Program. With more than 15 years of experience in early-stage investing and scaling corporate innovation, Plug and Play has a keen ability to identify, attract, and accelerate founders who want to solve industry challenges and scale new technologies,” Tan added.
Join the MiRXES Translator Program
Applications for the inaugural 2022-2023 MiRXES Translator Program will begin at the end of October 2022.
The program will be rolling out with six focus areas – diagnostic solutions, complementary health products, health management programmes, digital health solutions, healthcare financing solutions and healthcare supply chain.
Post-revenue startups across Asia-Pacific, Europe and North America, with innovations aimed at improving the quality and efficiency of preventive healthcare, are eligible to apply for this programme.
The MiRXES Translator Program supports startups in accelerating the commercialisation of their products through:
- Revenue contracts and/or benefits-in-kind of up to US$1,000,000 in value
- Scientific and clinical advisory
- Workflow optimisation and market positioning strategy
- Price and revenue channel discovery
- Expansion opportunities to target markets
- Access to a multi-stakeholder ecosystem of investors, policymakers, payors, solution providers and healthcare delivery providers, including MiRXES’s delivery arm
For more information about and to apply to the MiRXES Translator Program, visit their page here.
–
Disclosure: This article is produced by e27 team, sponsored by Plug and Play.
The post MiRXES launches SEA first Translator Program with Plug and Play appeared first on e27.